Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12631829 | 0.86 | CCNA2 (0.32) | EPHX1TSHRCCNA2CDK2MEN1 | |
| SCHEMBL12631824 | 0.83 | MEN1 (0.47) | HTTMEN1KMT2ALMNA | |
| SCHEMBL12631807 | 0.80 | HTT (0.34) | HTTCCNA2CDK2MEN1KMT2A | |
| SCHEMBL3174582 | 0.72 | STK17B (0.44) | JAK3EPHX1L3MBTL1TSHRCACNA1B | |
| SCHEMBL3168722 | 0.71 | STK17B (0.45) | JAK3EPHX1L3MBTL1CACNA1BBTK | |
| SCHEMBL3169517 | 0.71 | STK17B (0.38) | JAK3EPHX1L3MBTL1TSHRCACNA1B | |
| SCHEMBL12631844 | 0.71 | BRS3 (0.35) | LMNA | |
| SCHEMBL3174379 | 0.70 | STK17B (0.39) | JAK3L3MBTL1TSHRCACNA1BBTK | |
| SCHEMBL12631795 | 0.70 | AKT1 (0.33) | HTTCCNA2CDK2MEN1KMT2A | |
| SCHEMBL3165883 | 0.69 | JAK3 (0.40) | JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947694-B2 | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947694-B2 | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | CDK1, CDK2, CDK4 | LCK 308/4885JAK3 470/4885HTT 4081/4885 |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | CDK1, CDK2, CDKN1A | LCK 212/4885JAK3 587/4885HTT 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.